Published in AIDS on September 23, 2005
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 2.30
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
TLR-based immune adjuvants. Vaccine (2010) 2.10
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One (2008) 1.81
Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS (2010) 1.80
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 1.30
CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV-infected individuals. J Immunol (2008) 1.21
Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc (2007) 1.12
Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine (2009) 1.11
Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One (2011) 1.09
The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine (2009) 1.09
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine (2014) 1.07
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis (2012) 1.03
Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol (2008) 1.02
Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology (2009) 1.00
Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology (2007) 0.98
Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol (2014) 0.97
Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine (2007) 0.95
Vaccine adjuvants: mode of action. Front Immunol (2013) 0.94
Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology (2006) 0.92
Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol (2011) 0.91
Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One (2013) 0.88
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. Hum Vaccin Immunother (2013) 0.85
Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development. Clin Exp Immunol (2009) 0.85
Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells. J Immunol (2011) 0.85
Carbon nanotubes as vaccine scaffolds. Adv Drug Deliv Rev (2013) 0.84
CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J Immune Based Ther Vaccines (2008) 0.83
Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting. PLoS One (2013) 0.82
Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz (2010) 0.81
Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. J Immune Based Ther Vaccines (2008) 0.81
TLR7- and TLR9-responsive human B cells share phenotypic and genetic characteristics. J Immunol (2015) 0.80
Optically Triggered Immune Response through Photocaged Oligonucleotides. Tetrahedron Lett (2015) 0.80
CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses. Biomed Res Int (2013) 0.79
Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers. PLoS One (2014) 0.79
Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection. Cochrane Database Syst Rev (2014) 0.78
Organosilane and Polyethylene Glycol Functionalized Magnetic Mesoporous Silica Nanoparticles as Carriers for CpG Immunotherapy In Vitro and In Vivo. PLoS One (2015) 0.78
Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in HIV/ AIDS Patients: A Randomized Controlled Trial. Hepat Mon (2012) 0.78
Topical CpG adjuvantation of a protein-based vaccine induces protective immunity to Listeria monocytogenes. Clin Vaccine Immunol (2014) 0.77
Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model. Iran J Basic Med Sci (2012) 0.77
Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates. Immun Inflamm Dis (2016) 0.75
Monocyte-derived dendritic cells identified as booster of T follicular helper cell differentiation. EMBO Mol Med (2014) 0.75
In ovo delivery of CpG DNA reduces avian infectious laryngotracheitis virus induced mortality and morbidity. Viruses (2015) 0.75
Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore. Hum Vaccin Immunother (2017) 0.75
A monoclonal antibody against the human SUMO-1 protein obtained by immunization with recombinant protein and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother (2013) 0.75
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol (2002) 4.21
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol (2004) 3.10
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med (2005) 2.89
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev (2009) 2.54
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 2.48
Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J Immunol (2004) 2.33
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother (2004) 2.02
Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res (2005) 1.97
Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study. PLoS One (2009) 1.87
Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS (2007) 1.85
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol (2002) 1.80
Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol (2008) 1.78
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med (2007) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis (2005) 1.63
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54
TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J Immunol (2007) 1.49
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res (2007) 1.47
CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res (2003) 1.45
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother (2006) 1.44
Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem (2002) 1.43
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med (2011) 1.42
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
Sex, politics, and religion: why AIDS is a secular issue. J Int Assoc Physicians AIDS Care (Chic) (2004) 1.40
Circulating endothelial progenitor cell levels are not reduced in HIV-infected men. J Infect Dis (2012) 1.39
Twenty-five years of AIDS. CMAJ (2006) 1.39
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) (2011) 1.35
Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun (2004) 1.34
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.33
The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther (2004) 1.33
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine (2005) 1.33
Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine (2006) 1.33
Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis (2005) 1.32
Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis (2002) 1.30
Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis (2010) 1.30
CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res (2004) 1.25
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine (2004) 1.23
CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol (2004) 1.22
Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet (2010) 1.21
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr (2009) 1.19
Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol (2006) 1.18
Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol (2008) 1.18
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis (2008) 1.17
IL-10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/calmodulin-dependent protein kinase-activated p38 MAPK and Sp-1 and CREB-1 transcription factors. J Immunol (2007) 1.15
Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun (2002) 1.15
Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol (2003) 1.14
Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. Infect Immun (2008) 1.14
Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology (2004) 1.13
CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun (2004) 1.09
A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun (2006) 1.08
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad Sci U S A (2012) 1.08
Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis (2006) 1.07
High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol (2006) 1.07
Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res (2004) 1.06
Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer (2007) 1.06
A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine (2008) 1.05
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother (2008) 1.05
Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. PLoS Pathog (2010) 1.05
Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS (2002) 1.05
Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol (2002) 1.04
CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J Immunol (2003) 1.04
Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PLoS One (2013) 1.04
CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res (2003) 1.03
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis (2012) 1.03
CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res (2005) 1.02
Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol (2005) 1.02
Intracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells. J Biol Chem (2006) 1.02
Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol (2006) 1.02
A role for Toll in autoimmunity. Nat Immunol (2002) 1.01
Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol (2013) 1.01
Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev (2002) 1.00
Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther (2007) 1.00
Inaccuracy of death certificate diagnosis of tuberculosis and potential underdiagnosis of TB in a region of high HIV prevalence. Clin Dev Immunol (2012) 0.99
CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res (2004) 0.99
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine (2010) 0.98
Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol (2003) 0.98
Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology (2007) 0.98
Development and validation of the HIV Medication Readiness Scale. Assessment (2007) 0.97
Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review. PLoS One (2011) 0.97
Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol (2005) 0.97
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS (2006) 0.97
The role of psychological and behavioral variables in quality of life and the experience of bodily pain among persons living with HIV. J Pain Symptom Manage (2008) 0.97